title: Maintained reduction of uterine leiomyoma following addition of hormonal replacement therapy to a monthly luteinizing hormone-releasing hormone agonist implant: a pilot study.
abstract: Ten pre-menopausal women with uterine leiomyoma were treated for 1 year with a monthly depot of luteinizing hormone-releasing hormone agonist (LHRA-a), goserelin, combined after the initial 3 months of treatment with conjugated oestrogens 0.3 mg (days 1-25) and medroxy-progesterone acetate 5 mg (days 16-25). Mean leiomyoma volume decreased by 49.3% during the first 3 months when goserelin alone was administered but did not change significantly during the 9 months of combination therapy. There were no significant changes in bone mass or high-density lipoprotein cholesterol during the study whereas hot flushes and menstrual blood loss were well controlled. These results indicate that ovarian suppression with a monthly depot of the LHRH-a, goserelin, combined after 3 months with low-dose hormonal replacement therapy reduced the size and the symptomatology of leiomyoma while preserving the bone mass.
authors.affiliation: Research Centre, Hôpital St-François d'Assise, Quebec, Canada.
authors.forename: R
authors.initials: R
authors.lastname: Maheux
authors.forename: A
authors.initials: A
authors.lastname: Lemay
authors.forename: P
authors.initials: P
authors.lastname: Blanchet
authors.forename: J
authors.initials: J
authors.lastname: Friede
authors.forename: X
authors.initials: X
authors.lastname: Pratt
mesh_terms: D000328:Adult; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects; D002064:Buserelin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002784:Cholesterol / Q000097:blood; D003271:Contraceptive Agents, Female / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D015914:Estrogen Replacement Therapy; D004967:Estrogens / Q000097:blood; D004966:Estrogens, Conjugated (USP) / Q000627:therapeutic use*; D005260:Female; D017273:Goserelin; D006801:Humans; D007889:Leiomyoma / Q000188:drug therapy* / Q000473:pathology; D008525:Medroxyprogesterone / Q000031:analogs & derivatives / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008598:Menstruation / Q000187:drug effects; D008875:Middle Aged; D010865:Pilot Projects; D014280:Triglycerides / Q000097:blood; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000473:pathology
chemical_list: D000970:Antineoplastic Agents; D003271:Contraceptive Agents, Female; D004967:Estrogens; D004966:Estrogens, Conjugated (USP); D014280:Triglycerides; D017273:Goserelin; D002784:Cholesterol; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone; D002064:Buserelin